,
,
,
,
,
,
,
,
,
, Bibliographie 1. Compston A, Coles A. Multiple sclerosis, Lancet Lond Engl, vol.372, issue.9648, pp.1502-1519, 2008.
Effect of relapses on development of residual deficit in multiple sclerosis, Neurology. 9 déc, vol.61, issue.11, pp.1528-1560, 2003. ,
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis, J Neurol Sci. déc, vol.311, issue.1, pp.29-34, 2011. ,
Contribution of relapses to disability in multiple sclerosis, J Neurol. févr, vol.255, issue.2, pp.280-287, 2008. ,
Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, issue.20, pp.1430-1438, 2000. ,
Characterising aggressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.84, issue.11, pp.1192-1200, 2013. ,
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry. janv, vol.79, issue.1, pp.52-58, 2008. ,
Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. sept, vol.13, issue.8, pp.975-80, 2007. ,
Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis, Mult Scler Houndmills Basingstoke Engl. déc, vol.16, issue.12, pp.1490-1499, 2010. ,
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial, J Neurol Neurosurg Psychiatry. déc, vol.82, issue.12, pp.1344-50, 2011. ,
Immunomodulators and immunosuppressants for multiple sclerosis: a network metaanalysis. In: The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews ,
, , 2013.
,
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. In: The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews ,
, , 2015.
A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.387-401, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617764
Oral fingolimod (FTY720) for relapsing multiple sclerosis, N Engl J Med, vol.355, issue.11, pp.1124-1140, 2006. ,
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis, Mult Scler J. sept, vol.18, issue.9, pp.1269-77, 2012. ,
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, Lancet Neurol. juin, vol.13, issue.6, pp.545-56, 2014. ,
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, vol.362, issue.5, pp.402-415, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00617750
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis, Adv Ther, vol.31, issue.11, pp.1134-54, 2014. ,
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis, Brain, vol.138, issue.11, pp.3275-86, 2015. ,
Fingolimod for relapsing-remitting multiple sclerosis, The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews ,
, , 2016.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006. ,
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.911-923, 2006. ,
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study, Neurology. 3 mars, vol.72, issue.9, pp.806-818, 2009. ,
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL, J Neurol. mars, vol.256, issue.3, pp.405-420, 2009. ,
Early development of anti-natalizumab antibodies in MS patients, J Neurol. sept, vol.260, issue.9, pp.2343-2350, 2013. ,
, Progressive Multifocal Leukoencephalopathy Therapy. J Neurovirol. déc, vol.21, issue.6, pp.632-638, 2015.
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis, Ann Neurol. mars, vol.77, issue.3, pp.425-460, 2015. ,
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study, Neurology. 23 févr, vol.86, issue.8, pp.771-779, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01299977
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology. 22 janv, vol.58, issue.2, pp.169-78, 2002. ,
Mitoxantrone: a review of its use in multiple sclerosis, CNS Drugs, vol.18, issue.6, pp.379-96, 2004. ,
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry. févr, vol.62, issue.2, pp.112-120, 1997. ,
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome, J Neurol. mars, vol.244, issue.3, pp.153-162, 1997. ,
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, CAMMS223 Trial Investigators, vol.359, pp.1786-801, 2008. ,
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet, vol.380, pp.1819-1847, 2012. ,
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet, vol.380, pp.1829-1868, 2012. ,
Alemtuzumab more effective than interferon ?-1a at 5-year follow-up of CAMMS223 clinical trial, Neurology. 3 avr, vol.78, issue.14, pp.1069-78, 2012. ,
Alemtuzumab therapy for multiple sclerosis, Neurother J Am Soc Exp Neurother. janv, vol.10, issue.1, pp.29-33, 2013. ,
DOI : 10.1007/s13311-012-0159-0
URL : http://europepmc.org/articles/pmc3557360?pdf=render
Autorité de Santé-LEMTRADA (alemtuzumab), immunosuppresseur sélectif, p.22, 2017. ,
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study, J Neurol. avr, vol.260, issue.4, pp.1136-1182, 2013. ,
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol. mars, vol.13, issue.3, pp.257-67, 2014. ,
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study, Mult Scler Houndmills Basingstoke Engl. mai, vol.17, issue.5, pp.578-93, 2011. ,
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta, Lancet Neurol. avr, vol.9, issue.4, pp.381-90, 2010. ,
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, Lancet Lond Engl. 22 juin, vol.381, issue.9884, pp.2167-75, 2013. ,
DOI : 10.1016/s0140-6736(12)62190-4
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.373, issue.15, pp.1418-1446, 2015. ,
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial, Lancet Neurol. mai, vol.13, issue.5, pp.472-81, 2014. ,
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial, Lancet Lond Engl. 6 août, vol.388, pp.576-85, 2016. ,
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?, Ann Neurol. avr, vol.67, issue.4, pp.452-61, 2010. ,
Proinflammatory GM-CSFproducing B cells in multiple sclerosis and B cell depletion therapy, Sci Transl Med, vol.7, issue.310, pp.310-166, 2015. ,
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis, N Engl J Med. 14 févr, vol.358, issue.7, pp.676-88, 2008. ,
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial, Neurology. 8 juin, vol.74, issue.23, pp.1860-1867, 2010. ,
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy, Neurology, vol.87, issue.20, pp.2074-81, 2016. ,
Safety and clinical outcomes of Rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID), Arthritis Res Ther. 13 mai, vol.13, issue.3, p.75, 2011. ,
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID), J Neuroimmune Pharmacol. mars, vol.11, issue.1, pp.1-8, 2016. ,
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study, Neurology. 18 févr, vol.82, issue.7, pp.573-81, 2014. ,
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial, Ann Neurol. mars, vol.63, issue.3, pp.395-400, 2008. ,
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet Lond Engl, vol.378, issue.9805, pp.1779-87, 2011. ,
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.19, issue.3, pp.221-255, 2017. ,
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients: Rituximab vs Fingolimod, Ann Neurol. juin, vol.79, issue.6, pp.950-958, 2016. ,
Comparative effectiveness of Rituximab relative to IFN-? or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry, Mult Scler Houndmills Basingstoke Engl. 1 juin, p.1352458517713668, 2017. ,
Natalizumab for relapsing remitting multiple sclerosis, Cochrane Database Syst Rev, issue.10, p.7621, 2011. ,
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results, J Neurol Neurosurg Psychiatry, vol.85, issue.11, pp.1190-1197, 2014. ,
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet Lond Engl. 21 déc, vol.360, issue.9350, pp.2018-2043, 2002. ,
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis, Acta Neurol Belg. déc, vol.101, issue.4, pp.210-216, 2001. ,
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 ,
, Years. J Rheumatol, vol.42, issue.10, pp.1761-1767, 2015.
Public biotech 2012-the numbers, Nat Biotechnol. 8 août, vol.31, issue.8, pp.697-703, 2013. ,